West African Resources producing 150,000 ounces of gold per annum from 2019

Published 20-FEB-2017 10:17 A.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

On Monday morning West African Resources (ASX: WAF) released the Definitive Feasibility Study (DFS) for its Sanbrado gold project located in Burkina Faso.

Until recently, the Sanbrado project was referred to as the Tanlouka project which includes the high grade M1 South discovery, which is clearly the value driver as the company prepares to embark on an optimised DFS which will be modelled on a combined open pit and underground mining plan.

While the current DFS metrics are impressive, particularly for a company that has only come under the spotlight in the last 12 months, the optimised DFS is expected to feature substantially higher production metrics, reduced costs and longer mine life.

Low capex and short payback period with optimisation providing mine life extension

Given this will build on the current mine life of nearly 9 years with the first three years delivering annual production of 150,000 ounces, West African is shaping up as a prominent mid-tier African producer.

The metrics are strong with all in sustaining costs (AISC) of US$708 per ounce over the first three years, leaving a healthy margin of circa $500 per ounce based on the current gold price.

Upfront capital expenditure is US$131 million with a two year payback period based on DFS metrics. Importantly, the project is fully permitted and with West African having $17 million in cash management said it will not need to raise capital to complete the optimised DFS, as well as exploration drilling which should extend and convert resources.

Of course this is speculative at this stage and investors should seek professional financial advice if considering this stock for their portfolio.

Brokers like the story as Argonaut suggests WAF may be another Connelly M&A conquest

Mike Millikan from Hartleys pointed to the key highlights in the DFS in saying, “Sanbrado is a high quality project with a robust and growing mining inventory, simple processing flow sheet, meaningful production profile and healthy mine life”.

Prior to the release of the DFS Hartleys had a 12 month price target of 55 cents on WAF, representing upside of 100% to Friday’s closing price of 27.5 cents

James Wilson from Argonaut sees West African as a potential takeover target, recently pointing to a number of factors that could attract merger and acquisition activity.

Wilson said, “There are only a small number of near-term production ready assets listed on the ASX and WAF’s project is located in a mining friendly country, has near surface and high-grade ores, as well as established power and road infrastructure with several key developed and undeveloped gold mines located within close proximity to the project which would make Sanbrado an attractive ore source, or centralised processing hub to improve the economics and/or scale of nearby operators”.

It should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

WAF Executive Chairman, Mark Connelly has headed up the development of two other major gold projects in Africa that have been the subject of merger and acquisition activity, the most recent being previously ASX listed Papillon Resources which delivered shareholders a premium takeover price as its suitor moved on the verge of completion of an impressive DFS.

As WAF embarks on a potentially value enhancing optimised DFS it will be interesting to see if the M&A activity which Wilson is alluding to materialises.

Due to West African’s dual listing compliance requirements the current mining inventory doesn’t include any inferred material. This is significant in that it places a conservative slant on the group’s potential reserves position, production profile and life of mine, indicating that as resources are converted to the indicated category project dynamics will look even better.

Hyde notes near 100% conversion of inferred resources to indicated resources

On this note Managing Director, Richard Hyde said, “The pits at M1 South are currently bouncing off the bottom of data so we are getting effectively 100% conversion of indicated resources, and we would get high conversion of inferred resources if we were allowed to include them”.

There is approximately 600,000 inferred ounces of ore at over 2 grams per tonne across the whole project and Hyde is looking to get these ounces converted to indicated status with a view to incorporating them in the updated mine schedule over the coming months and into next year.

Consequently, while the DFS is important in terms of establishing a base case scenario, and essential in bringing Sanbrado into production and generating cash, it could be argued that the project’s full potential will be better realised following the release of the optimised DFS.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free